Presenting: Arkana Therapeutics – Beyond GLP-1 Weight Loss
Details
Arkana Therapeutics — Co-Founder Jack Gugel presenting — is a biotechnology company developing next-generation obesity treatments inspired by nature's most extreme metabolic adaptations.
More than 1 billion people worldwide are affected by obesity, yet many patients discontinue GLP-1 therapies like Ozempic due to side effects or difficulty maintaining treatment. As a result, weight regain remains a significant challenge and highlights the need for alternative therapies.
Arkana Therapeutics studies animals with unique metabolic traits, such as the Burmese python, to discover naturally evolved molecules that regulate appetite and energy balance. Their lead candidate, ARK-100, is an orally available appetite suppressant with a novel non-GLP-1 mechanism, while ARK-200 is designed to increase energy expenditure through skeletal muscle metabolism. Together, these programs aim to provide new options for obesity treatment with improved tolerability and long-term outcomes.
Our target market is patients with obesity, healthcare providers, and pharmaceutical partners worldwide who need effective, well-tolerated weight management therapies and are willing to pay for improved health outcomes and sustainable weight loss.
Our competition is GLP-1 therapies such as Ozempic and Wegovy, other obesity drug developers, and metabolic disease biotech companies. Our competitive advantage is discovering therapeutics from naturally evolved biological systems and developing novel mechanisms that address obesity beyond traditional GLP-1 pathways.
The total market size in 2024 is the global obesity treatment market, and the total market revenue in 2024 is $20B+, with continued rapid growth expected.
Top 3 challenges:
- Raising capital to advance clinical development
- Building a world-class scientific and operational team
- Advancing the science and validating novel therapeutic mechanisms
Our PitchBoulder ask: We're looking for candid feedback on our pitch from both investors and operators. What parts of the story are compelling? What questions remain unanswered? Where can we improve clarity, credibility, or investor confidence as we continue building the company?
